The European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long-term outcomes in patients with ankylosing spondylitis treated with infliximab

F. Heldmann, Mark J. Brandt, I.E. van der Horst-Bruinsma, R. Landewe, J. Sieper, G. R. Burmester, F. van den Bosch, K. de Vlam, P. Geusens, H. Gaston, S. Schewe, T. Appelboom, P. Emery, M. Dougados, M. Leirisalo-Repo, M. Breban, Joachim Listing, J. Braun

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)672-680
JournalClinical and Experimental Rheumatology
Volume29
Issue number4
Publication statusPublished - 2011

Keywords

  • ankylosing spondylitis
  • anti-TNF
  • infliximab

Cite this

Heldmann, F., Brandt, M. J., van der Horst-Bruinsma, I. E., Landewe, R., Sieper, J., Burmester, G. R., van den Bosch, F., de Vlam, K., Geusens, P., Gaston, H., Schewe, S., Appelboom, T., Emery, P., Dougados, M., Leirisalo-Repo, M., Breban, M., Listing, J., & Braun, J. (2011). The European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long-term outcomes in patients with ankylosing spondylitis treated with infliximab. Clinical and Experimental Rheumatology, 29(4), 672-680.